TG Therapeutics Raises 2024 Revenue Guidance Amid Soaring BRIUMVI Sales
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
- Latest
- Trending
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Financial advisors are now diversifying billing methods, yet asset-based fees endure. Cody Lachner's firm embraces both subscriptions and AUM.
"Apple Services to see AI-driven growth from 2024-2026, says BofA; projected 14% YOY revenue increase in 2024 with strong subscription ...
Explore what top VCs are excited about in AI—focused on infrastructure tech, unstructured data, and industry-specific solutions. Avoid crowded markets.
Binance restricts European users from copy trading and limits unauthorized stablecoins, complying with new MiCA regulations effective June 30, 2024.
"Salesforce COO Brian Millham sold $495,621 in shares, bought $380,107 in new shares. Part of Rule 10b5-1, strong Q1, analysts ...
Progress Software surpasses Q2 earnings with $1.08 EPS and $175M revenue but provides conservative guidance for Q3 2024, citing steady ...
Discover GrimResource: A new hacking method exploiting Microsoft Management Console files. Learn how to protect yourself from this emerging threat.
Salesforce exec Srinivas Tallapragada sells $228K in shares to cover taxes; Salesforce sees 11% revenue rise, strong market position, and ...
Kaltura's Chief Customer Officer Natan Israeli sells company stock under a 10b5-1 plan, retaining a strong shareholding, reflecting confidence in ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.